Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
MESO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.78 - $22.00
Previous CloseN/A
Volume155.35K
Average Volume (3M)211.48K
Market Cap
$1.49B
Enterprise Value$6.60B
Total Cash (Recent Filing)$38.03M
Total Debt (Recent Filing)$126.11M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 27, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding127,778,220
10 Day Avg. Volume197,809
30 Day Avg. Volume211,484
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-4.59
Enterprise Value/Market Cap4.44
Enterprise Value/Revenue273.24
Enterprise Value/Gross Profit-292.32
Enterprise Value/Ebitda-30.44
Forecast
1Y Price Target
$30.00Price Target Upside143.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Mesoblast News
PremiumCompany Announcements
Mesoblast Updates Securities Status with ASX
PremiumCompany Announcements
Mesoblast Announces Director Securities Changes Following AGM Approval
Bulls Say, Bears Say
Bulls Say
Funding And Financial SupportMesoblast is funded well into 2026, potentially extending further depending on the launch trajectory of Ryoncil in pediatric steroid refractory acute graft vs. host disease.
Market OpportunityThe potential pricing for Ryoncil in excess of $1.5M for a full course supports a significant market opportunity, validating the view that the GvHD opportunity alone could support Mesoblast's current valuation.
Regulatory ApprovalFDA approval of Ryoncil represents a watershed moment for Mesoblast, leading to a reduction in revenue risk adjustment and an increase in the 12-month price target.
Bears Say
CompetitionRyoncil's approval as the only drug for patients under 12 could provide a competitive advantage, especially in the 12-18 year-old segment where it overlaps with Jakafi.
Pricing StrategyThe announced WAC pricing of $1.55M for Ryoncil is based on health economic analyses suggesting a total health economic benefit in the range of $3.2M-$4.1M, with the opportunity in pediatric SR-aGvHD estimated at ~$600M in the US.
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.51% Other Institutional Investors
99.01% Public Companies and Individual Investors
MESO FAQ
What was Mesoblast Ltd’s price range in the past 12 months?
Mesoblast Ltd lowest stock price was $5.78 and its highest was $22.00 in the past 12 months.
What is Mesoblast Ltd’s market cap?
Mesoblast Ltd’s market cap is $1.49B.
When is Mesoblast Ltd’s upcoming earnings report date?
Mesoblast Ltd’s upcoming earnings report date is Aug 27, 2025 which is in 70 days.
How were Mesoblast Ltd’s earnings last quarter?
Currently, no data Available
Is Mesoblast Ltd overvalued?
According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued.
Does Mesoblast Ltd pay dividends?
Mesoblast Ltd does not currently pay dividends.
What is Mesoblast Ltd’s EPS estimate?
Mesoblast Ltd’s EPS estimate is -0.31.
How many shares outstanding does Mesoblast Ltd have?
Mesoblast Ltd has 127,778,220 shares outstanding.
What happened to Mesoblast Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mesoblast Ltd?
Currently, no hedge funds are holding shares in MESO
Mesoblast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (143.90% Upside)
$30.00 (143.90% Upside)
Blogger Sentiment
Bullish
MESO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
61.59%
12-Months-Change
Fundamentals
Return on Equity
-21.26%
Trailing 12-Months
Asset Growth
-2.53%
Trailing 12-Months
Company Description
Mesoblast Ltd
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MESO Company Deck
MESO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements including the FDA approval of RYONCIL, successful fundraising, and promising clinical trial results. However, the company faces some challenges such as non-cash balance sheet impacts and ongoing trial enrollments.Read More>Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Kymera Therapeutics
―
Immunocore Holdings
―
Vera Therapeutics
―